Patient Perception Study for AL-4943A

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT01294969
First received: February 10, 2011
Last updated: December 14, 2012
Last verified: October 2011
  Purpose

To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.


Condition Intervention Phase
Allergic Conjunctivitis
Drug: AL-4943A
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Overall Patient satisfaction [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Enrollment: 47
Study Start Date: September 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AL-4943A
One drop per day in both eyes
Drug: AL-4943A
Once daily topical ocular allergy medication used for 7 days

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of allergic conjunctivitis within last 24 months
  • Active signs and symptoms of ocular allergies

Exclusion Criteria:

  • Severe or serious ocular condition, ocular surgical intervention, ocular infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01294969

Locations
United States, Texas
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01294969     History of Changes
Other Study ID Numbers: SMA-10-15
Study First Received: February 10, 2011
Last Updated: December 14, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Alcon Research:
Allergic conjunctivitis

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Olopatadine
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Allergic Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 20, 2014